[{"from": "human", "value": "Provide a description of this molecule. [C][C@H1][Branch1][=Branch1][C][Branch1][C][C][C][C@][Branch2][#Branch1][Branch2][C][C][C@@][Branch2][=Branch1][P][C@H1][C][C][C@H1][C@][Branch2][=Branch1][Branch2][C][O][C][C@][Ring1][=Branch1][Branch2][Ring1][Branch1][C][Ring1][#Branch2][=C][C][C@][Ring1][=C][Branch1][#Branch2][C@@H1][Ring2][Ring1][C][C][=Branch1][C][=O][O][C][C][C@H1][Branch2][Ring1][Branch1][C@@H1][Ring1][P][O][C][C@@][Branch1][C][C][Branch1][=Branch2][C][Branch1][C][C][Branch1][C][C][C][N][N][C][=Branch1][=Branch1][=N][C][=N][Ring1][Branch1][C][=C][C][=N][C][=C][Ring1][=Branch1][C][C][C]"}, {"from": "gpt", "value": "The molecule is a novel enfumafungin derivative oral triterpene antifungal approved for the treatment of vulvovaginal candidiasis (VVC), also known as a vaginal yeast infection. It was developed out of a need to treat fungal infections that may have become resistant to echinocandins or azole antifungals. Ibrexafungerp is orally bioavailable compared to the echinocandins [caspofungin], [micafungin], and [anidulafungin]; which can only be administered parenterally. Similar to echinocandins, ibrexafungerp targets the fungal \u03b2-1,3-glucan synthase, which is not present in humans, limiting the chance of renal or hepatic toxicity.  Ibrexafungerp was granted FDA approval on 1 June 2021."}]